Moonrise Medical Lands $500,000 Investment

Summary:

Moonrise Medical, a Canadian medical device startup based in Hamilton, Ontario, announced a significant development in its innovative ultrasound technology aimed at vascular assessment. The company has secured a $500,000 investment from the Ontario Centre of Innovation (OCI) under the Life Sciences Innovation Fund (LSIF), which will expedite the development and commercialization of its advanced ultrasound system designed specifically to diagnose peripheral artery disease (PAD).

This groundbreaking system is notable for its ability to simplify and automate the process of PAD assessment by combining state-of-the-art imaging hardware with proprietary software that measures blood flow in real-time. This innovation positions Moonrise Medical’s device as a quicker and more accessible alternative to traditional vascular testing methods.

Adam Gold, the CEO of Moonrise Medical, expressed enthusiasm about the OCI funding, stating that it validates the company’s mission and will facilitate faster progress toward clinical validation and regulatory approval, ultimately bringing their technology to patients in urgent need. The investment plays a crucial role in propelling Moonrise Medical toward its key objectives.

Moonrise Medical's funding comes as part of a larger initiative where 13 life sciences companies in Ontario received support from the LSIF, which is managed by OCI in collaboration with the Ministry of Economic Development, Job Creation and Trade. The LSIF aims to assist early-stage companies in commercializing pioneering health technologies, significantly contributing to Ontario’s economic growth.

Furthermore, Abubaker Khalifa, MD, the chief operating officer, highlighted that the funding would aid in expanding their team, completing essential clinical studies, and preparing for regulatory submissions. This investment is viewed as a vital leap forward in improving healthcare outcomes for patients suffering from vascular diseases.

Headquartered in Hamilton, Moonrise Medical is proactively collaborating with notable vascular specialists and research institutions to validate its innovative diagnostic platform. This emphasis on partnerships signifies the company's commitment to evidence-based development and underscores its goal to enhance vascular diagnostics.

As it continues on its path to commercialization, Moonrise Medical's flagship product aims to provide a quick, operator-independent evaluation of blood flow, potentially transforming how PAD is detected and treated. With innovation at its core and with the support of the LSIF, Moonrise Medical is poised to make a significant impact in the realm of vascular health and patient care.

For more information, visit their official website at www.moonrisemedical.com.